Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Shoulder Innovations, Inc.NYSE: SI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows 79.7% year over year
Q1 FY2026 net income of $8.38M (cash outflow) rose 79.7% year over year. Sequentially, it rose 7.8% from the prior quarter.
Context
- Net income amounted to 85.3% of revenue in FY2025, up 35.9 pp from a year earlier.
- Net income grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$34.92M (-13.5%) for the fiscal year ending Dec 2026, a slowdown from the +158.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.38M+7.8% QoQ
- Last fiscal yearDec 2025
- -$40.36M+158.4% YoY
- LTMMar 2026
- -$44.08M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +79.7% | -50.2% | -129.9 pp |
| 1 year | +158.4% | -13.5% | -171.9 pp |
| 3-year CAGR | — | -7.0% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (40.36M) USD
- Year-over-year change
- -158.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (40.36M) | -158.4% |
| FY2024 | 2024-12-31 | (15.62M) | -23.4% |
| FY2023 | 2023-12-31 | (12.66M) | — |
Net Income vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 net income of $44.08M is the 6th largest of the 11 companies compared; the peer median is $49.9M.
- Net income amounts to 81.8% of revenue for SI, versus a peer median of 13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $75.02M | +40.2% | -10.7% | 576.1% | |
| LTM Mar 2026 | $74.85M | -34.2% | -20.6% | 63.7% | |
| LTM Mar 2026 | $69.87M | +152.1% | +61.9% | — | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $57.09M | -16.9% | +0.6% | — | |
| LTM Mar 2026 | $44.08M | — | — | 81.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M | +84.6% | +27.3% | — |
| LTM Mar 2026 | $24.9M | -9.4% | -35.2% | 7.1% | |
| FY2025 | $14.41M | -41.7% | -27.6% | 13.4% | |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| LTM Mar 2026 | $4.24M | +113.0% | — | 9.6% | |
| Peer median (excluding SI) | $49.9M | -13.1% | -12.4% | 13.4% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 451K | 754K | 996K |
| Change in Working Capital | (4.77M) | (1.04M) | 0 |
| Accounts Receivables | (2.69M) | (575K) | (3.3M) |
| Inventory | (2.41M) | (4.03M) | (7.64M) |
| Accounts Payables | (737K) | 3.12M | 3.37M |
| Other Working Capital | 1.08M | 446K | 0 |
| Other Non-Cash Items | 2.18M | (437K) | 7.54M |
| Operating Cash Flow | (13.14M) | (14.14M) | (28.61M) |
| Capital Expenditures | (2.75M) | (4.02M) | (7.41M) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (29.25M) | (5.28M) | (119.49M) |
| Sales of Investments | 3.03M | 23.26M | 31.3M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (28.97M) | 13.96M | (95.6M) |
| Debt Repayment | 10M | 0 | 0 |
| Common Stock Issued | 34.88M | 66K | 39.51M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (149K) | 66K | 144.96M |
| Financing Cash Flow | 44.73M | 66K | 144.96M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | 2.61M | (113K) | 20.75M |
| Free Cash Flow | (15.89M) | (18.16M) | (36.02M) |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.